Provided by Tiger Trade Technology Pte. Ltd.

Lipocine

2.06
-0.0300-1.44%
Post-market: 2.060.00000.00%19:30 EDT
Volume:26.73K
Turnover:55.62K
Market Cap:16.98M
PE:-1.13
High:2.10
Open:2.07
Low:2.05
Close:2.09
52wk High:12.37
52wk Low:1.81
Shares:8.24M
Float Shares:6.55M
Volume Ratio:0.97
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8181
EPS(LYR):-1.7669
ROE:-60.94%
ROA:-37.04%
PB:0.78
PE(LYR):-1.17

Loading ...

What's Going On With Lipocine Stock On Monday?

Benzinga
·
Apr 06

Lipocine Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Apr 06

HC Wainwright Downgrades Lipocine to Neutral From Buy

MT Newswires Live
·
Apr 06

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Apr 06

Lipocine Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Lipocine CEO Makes Bold Insider Move, Signaling Strong Confidence Ahead

TIPRANKS
·
Apr 03

Lipocine CEO Mahesh V. Patel acquires shares worth $0.1 million

Reuters
·
Apr 03

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Benzinga
·
Apr 02

Lipocine weighs path after LPCN 1154 Phase 3 miss

TIPRANKS
·
Apr 02

Lipocine Updates Investor Presentation to Refine Market Messaging

TIPRANKS
·
Apr 02

Lipocine Shares Plumb New Lows After Postpartum Depression Study Failure

Dow Jones
·
Apr 02

Lipocine Shares Touch Record Low After Co's Postpartum Depression Pill Missed Late-Stage Trial Goal; Last Down 78.1%

THOMSON REUTERS
·
Apr 02

Lipocine Shares Plunge 78.4% Premarket After Co's Postpartum Depression Pill Missed Late-Stage Trial Goal

THOMSON REUTERS
·
Apr 02

BRIEF-Lipocine Reports Topline Safety & Efficacy Results For LPCN 1154 In Patients With Postpartum Depression

Reuters
·
Apr 02

Lipocine oral brexanolone misses primary endpoint in Phase 3 postpartum depression trial

Reuters
·
Apr 02

Lipocine Inc - 1154 Shows Statistically Significant Ham-D Reductions in Psychiatric History Subset

THOMSON REUTERS
·
Apr 02

Lipocine Inc - No Severe Adverse Events or Discontinuations Reported for Lpcn 1154

THOMSON REUTERS
·
Apr 02

Lipocine Inc - 1154 Phase 3 Primary Endpoint Not Met in Ppd Patients

THOMSON REUTERS
·
Apr 02

Lipocine Reports Topline Safety and Efficacy Results for Lpcn 1154 in Patients With Postpartum Depression

THOMSON REUTERS
·
Apr 02